GlassScriptPhysician profile
Dilpreet Singh
NPI 1710273339
$7,416.44
in general payments reported to CMS, 2019-2025
29 companies · $734 in 2025
The $734 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $2,421 · 2021: $895 · 2022: $889 · 2023: $1,450 · 2024: $264 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837 · Travel and Lodging: $582 · Education: $28.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,837.01 |
| Travel and Lodging | $581.92 |
| Education | $28.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,151.63 | 2019-2024 | Mitraclip, Accent |
| Novartis Pharmaceuticals Corporation | $748.09 | 2019-2021 | |
| Boston Scientific Corporation | $746.24 | 2020-2023 | |
| Amgen INC. | $615.54 | 2020-2025 | Tezspire, Repatha |
| Intuitive Surgical, INC. | $610.77 | 2023-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $582.15 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Janssen Pharmaceuticals, INC | $474.96 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $177.86 | 2023-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Pulmonx Corporation | $146.04 | 2023 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Insmed, INC. | $131.44 | 2022-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $130.72 | 2022-2023 | Opsumit, Uptravi |
| Ethicon US, LLC | $127.72 | 2022 | |
| Ethicon INC. | $126.57 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.78 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.06 | 2025 | Aralast |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.02 | 2023-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $60.41 | 2022-2023 | Yupelri |
| Verona Pharma, INC. | $49.52 | 2025 | Ohtuvayre |
| Medtronic, INC. | $48.41 | 2023 | Micra |
| Viatris Specialty LLC | $31.70 | 2025 | Yupelri |
| Genzyme Corporation | $27.98 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $27.78 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $25.83 | 2025 | Dupixent |
| United Therapeutics Corporation | $24.69 | 2023 | Tyvaso |
| Philips North America LLC | $23.99 | 2024 | (2383) Sleepundivided |
| American Regent | $16.65 | 2024 | Injectafer |
| Ars Pharmaceuticals Operations, INC. | $16.48 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $14.61 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilpreet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.